A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 31/20 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique
A61K 31/7004 - Monosaccharides ayant uniquement des atomes de carbone, d'hydrogène et d'oxygène
2.
Drug supply cartridge with visual use indicator and delivery devices that use the same
A drug delivery device and cartridge wherein the cartridge includes a movable use indicator that indicates whether the cartridge has been opened and/or used.
A61M 5/50 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras avec des moyens pour empêcher la réutilisation ou pour indiquer si le dispositif est défectueux, usagé, non stérile ou si l'on a tenté de l'utiliser
A61M 5/19 - Seringues avec plusieurs compartiments
A61M 5/28 - Ampoules ou cartouches-seringues, c.-à-d. ampoules ou cartouches munies d'une aiguille
A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
3.
Medical Containers And System Components With Non-Dehp Plasticizers For Storing Red Blood Cell Products, Plasma And Platelets
A container for blood or a blood component is provided, the container comprising one or more container walls defining an interior chamber, the container walls comprising one or more layers, the layers comprising or consisting of a composition comprising one or more polymeric materials and at least one extractable agent selected from the group consisting of a terephthalate ester, a cyclohexane dicarboxylic acid ester, a citrate ester, and a polyol ester, wherein the container further comprises one or more additional components, wherein the container comprises less than about 3% (w/w) of di-2-ethylhexyl phthalate (DEHP), preferably wherein the container comprises less than about 3% (w/w) of phthalates. Thereby, improved blood products are provided in which the DEHP or overall phthalate content is reduced.
The present invention relates to a medical bag (1), which is filled with an enteral or parenteral food solution and comprises at least one first chamber (12a). The bag (1) is made from welded-together plastic films (11). An inner container (20) is inserted in the bag (1), said inner container comprising a port (30d-30h) which is welded into a weld seam (14a) of the bag (1).
A medical package is made from a multi-layer film and is filled with a medical liquid for infusion and/or for parenteral nutrition. The medical package has at least one weld seam and at least one inner layer of a matrix-phase polymer system, an intermediate layer of a matrix-phase polymer system, and an outer layer of a matrix-phase polymer system.
A61J 1/14 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques DétailsAccessoires à cet effet
B32B 3/08 - Caractérisés par des caractéristiques de forme en des endroits déterminés, p. ex. au voisinage des bords caractérisés par des éléments ajoutés à des endroits déterminés
B32B 27/08 - Produits stratifiés composés essentiellement de résine synthétique comme seul composant ou composant principal d'une couche adjacente à une autre couche d'une substance spécifique d'une résine synthétique d'une sorte différente
B32B 27/30 - Produits stratifiés composés essentiellement de résine synthétique comprenant une résine vinyliqueProduits stratifiés composés essentiellement de résine synthétique comprenant une résine acrylique
B32B 27/32 - Produits stratifiés composés essentiellement de résine synthétique comprenant des polyoléfines
An air injector (1, 1') for an infusion system (2, 2') comprises an air container (10, 10'); a connecting device (11) adapted to establish a fluid connection (C1) between the air container (10, 10') and a liquid container (20) of the infusion system (2, 2') so as to allow air (A) from the air container (10, 10') to be injected into the liquid container (20); and a valve (12) arranged in the fluid connection (C1)
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
A61M 5/155 - Perfusion sous pression, p. ex. utilisant des pompes utilisant des réservoirs sous pression, p. ex. au moyen de pistons mis sous pression par un gaz
An Infusion assembly comprises a tube (1), a connector (20a, 20b) comprising a connection portion (200a, 200b) configured to be engageable with the tube (1), and a joining agent (30) adapted for solvent bonding the connection portion (200a, 200b) with the tube (1), wherein the connection portion (200a, 200b) comprises a receiving surface (202a, 202b) for receiving the joining agent (30). The joining agent (30) comprises a polar solvent and a styrene block copolymer.
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
A61M 39/12 - Raccords ou accouplements pour tubes pour raccorder un tube flexible à un dispositif de fixation rigide
B29C 65/48 - Assemblage d'éléments préformésAppareils à cet effet en utilisant des adhésifs
F16L 33/34 - Dispositions d'assemblage des manches avec des organes rigidesRaccords rigides pour manches, p. ex. éléments unitaires s'engageant à la fois dans deux manches avec une liaison obtenue par vulcanisation, collage, fusion ou similaire
9.
AMPOULE FOR A MEDICAL, IN PARTICULAR OPHTHALMOLOGICAL, LIQUID
The present invention relates to an ampoule (10) for a medical, in particular ophthalmological, liquid, comprising: a trunk part (5) for receiving the medical liquid; a foot part (6) for arranging a label (9), wherein the foot part (6) adjoins the trunk part (5) below the trunk part; a shoulder part (4) which adjoins the trunk part (5) above the trunk part; a neck part (3) which adjoins the shoulder part (4) above the shoulder part; a head part (2) which adjoins the neck part (3) above the neck part, with an applicator opening (2a) for removing the medical liquid from the ampoule (10); and a twist-off part (1) as a closure, which in an initial state of the ampoule (10) is connected to the head part (2) via an predetermined breaking point (1a) and seals the applicator opening (2a) in a fluid-tight manner. The ampoule is characterised in that the head part (2) is designed as an ellipsoidal portion, preferably as a spherical portion, with at least one upper base face in which the applicator opening (2a) is located.
Disclosed is a method and a system for producing an ampoule filled with a medical liquid. A preform is produced by plastic injection moulding that is then inhomogeneously heated and blown to form an ampoule body. Further disclosed is an ampoule produced by means of stretching and blowing, which comprises a connector with a break-off part in which the predetermined breaking point is aligned with the septum of the connector.
A drug delivery device has a housing with an adhesive pad associated with the lower surface of the housing and configured to removably attach to a human body surface. A drug reservoir is positioned within the housing and includes an outlet with a valve, with a needle fluidically connected to the reservoir and configured to define at least a portion of a fluid flow path between the reservoir and the human body surface. A controller is configured to control the components of the drug delivery device to execute a drug delivery routine. The drug delivery device also includes pressurized fluid positioned to apply a force to the reservoir. The controller moves the valve from a closed condition to an open condition during a drug delivery routine to allow the pressurized fluid to deform the reservoir or move a plunger to convey the drug out of the reservoir via the outlet.
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
A61M 5/145 - Perfusion sous pression, p. ex. utilisant des pompes utilisant des réservoirs sous pression, p. ex. au moyen de pistons
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
14.
PROCESS FOR MANUFACTURING AN OIL-AN-WATER EMULSION WITH A LOW PFAT5 VALUE IN ADMIXTURES FOR PARENTERAL NUTRITION
The invention relates to a process for manufacturing oil-in-water emulsions with a PFATs value that remains below 0.05% for at least 24 hours, preferably for at least 48 hours after admixing the emulsions with an amino acid and a glucose solution suitable for parenteral administration.
A61K 31/7004 - Monosaccharides ayant uniquement des atomes de carbone, d'hydrogène et d'oxygène
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 31/047 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates ayant plusieurs groupes hydroxyle, p. ex. sorbitol
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
A drip chamber for a fluid administration system, comprising: a reservoir (3, 3′) comprising an inlet orifice (5) at a top end region (13A) for inserting a fluid, and an outlet orifice (7, 7′) at a bottom end region (13B), wherein the bottom end region (13B) is located in gravitational direction opposite and below the top end region (13A), wherein a plunger element (11, 11′) moveably arranged within the reservoir (3, 3′) between a first position in the top end region (13A) and a second position in the bottom end region (13B), wherein the plunger element (11, 11′) comprises a fluid conducting channel (15) for regulating the flow of fluid from the inside of the reservoir (3, 3′) to the outlet orifice (7, 7′) when the plunger element (11, 11′) is located in the second position.
A port cannula (1) for puncturing a port (2) comprises: a base (10) and a needle (11) extending through the base (10), wherein a tip (110) of the needle (11) is arranged at a first side (A) of the base (10), wherein the needle (11) is displaceable relative to the base (10) to adjust a distance (L1, L2) of the needle (11) tip (110) to the base (10), wherein the base (10) has a support (100; 100'; 100'') at which the needle (11) is bendable at a second side (B) of the base (10) opposite the first side (A).
A61M 5/46 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras avec des moyens pour commander la profondeur de pénétration
A61M 5/32 - AiguillesParties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchonAccessoires pour introduire l'aiguille dans le corps ou l'y maintenirDispositifs pour la protection des aiguilles
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections; Pharmaceutical preparations for the treatment of autoimmune diseases, illnesses and conditions; Pharmaceutical preparations, namely, immunosuppressants; Pharmaceutical preparations for the treatment of plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis, polyarticular juvenile idiopathic arthritis and active enthesitis related arthritis, Crohn's disease, ulcerative colitis, hidradenitis colitis, hidradenitis suppurativa and non-infectious uveitis; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Biologics, namely, biological preparations for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections; Biologics, namely, biological preparations for the treatment of ankylosing spondylitis; Biological preparations for the treatment of and reducing signs and symptoms in adult patients with active ankylosing spondylitis; Protein therapeutics, namely, protein supplements; Pharmaceutical preparations for treating ankylosing spondylitis; Pharmaceutical preparations for the treatment of and for reducing signs and symptoms in adult patients with active ankylosing spondylitis
A port cannula (1; 1') for puncturing a port (2) comprises: a housing (10; 10') and a needle (11) having a tip (110), wherein the housing (10; 10') comprises a first part (100; 100'; 100'') and a second part (101; 101') rotatable with respect to one another to adjust a distance (L1, L2) of the needle (11) tip (110) to the housing (10; 10').
A61M 5/46 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras avec des moyens pour commander la profondeur de pénétration
A method for manufacturing a tube for an infusion set (S) comprises: providing a tube (1) and predetermining a distance (D) from an end (11) of the tube (1). The method further comprises: creating an impression (10) on the tube (1) at the predetermined distance (D) from the end (11) of the tube (1).
A medicament delivery device and method of use thereof. The device includes a sensor module and an injector module. The injector module is adapted to (i) be coupled to the sensor module during injection of a cannula and a needle into subcutaneous tissue and during delivery of the medicament and (ii) be removed from the sensor module after the delivery of the medicament.
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
An installation for producing a parenteral nutrition is described. The installation includes a pump with which liquids can be transferred from a plurality of source containers into a target container. The installation has a modular construction and includes a weighing module and a main module with the pump.
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
B65B 3/00 - Emballage de matériaux plastiques, de semi-liquides, de liquides ou de liquides et solides mélangés, dans des réceptacles ou récipients individuels, p. ex. dans des sacs ou sachets, boîtes, cartons, bidons ou pots
A port catheter system for delivery of a liquid to a patient, comprising: a port (3) comprising a chamber (31) and a connecting element (33) which is in liquid communication with the chamber (31), and which forms a liquid passageway from the chamber (31); and a catheter (5) comprising an elongated flexible tube with a first end (51) connectable or connected to the connecting element (33) and a second end (53) located opposite the first end (51), wherein a liquid contained within the chamber (31) and within the catheter (5), and at least one sealing element (7), wherein the chamber (31) and catheter (5) are sealed with the at least one sealing element (7) to hold the liquid therein. Also described is a port catheter set comprising a port (1) and a container (200).
A sealing element is received between a connector and an attachment member. The sealing element includes a foot section received by a recess of the connector, a shoulder engaging an inner surface of the attachment member, and a flange engaging a support surface of the connector. The sealing element also includes a cylindrical body extending from the shoulder to the flange along an insertion direction and, where the cylindrical body deforms to create a flow path through the sealing element, and a sealing head defines an opening that transitions from a closed state to an open state when the cylindrical body deforms.
The present invention relates to a novel protein formulation. In particular, the invention relates to a liquid pharmaceutical composition of an antibody directed to Interleukin-6 receptor, a method of manufacturing the composition, a kit including the composition, a package including the composition and to methods of treatment using the composition and/or package.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
28.
Methods of purifying and producing an adalimumab antibody
The present invention relates to a method for purifying adalimumab or a biosimilar thereof from a sample comprising adalimumab or a biosimilar thereof and impurities, through the use of hydroxyapatite resin in a Bind/Elute (B/E) mode under conditions such that the adalimumab or a biosimilar thereof binds to the resin and at least a portion of the impurities remain unbound. The invention is also concerned with a pharmaceutical compositions=of the purified adalimumab or a biosimilar thereof, and adalimumab or a biosimilar thereof obtainable by the process of the invention.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
B01D 15/38 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction spécifique non couverte par un ou plusieurs des groupes , p. ex. chromatographie d'affinité, chromatographie d'échange par ligand ou chromatographie chirale
B01J 20/04 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant des composés des métaux alcalins, des métaux alcalino-terreux ou du magnésium
C07K 1/20 - Chromatographie de partage, de phase inverse ou d'interaction hydrophobe
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
An assembly includes an injection device including a container for a product. The container includes a distal tip encompassing a channel providing a passageway for transferring the product, and an adaptor mounted onto the distal tip. The assembly further includes a heat-shrinkable film covering at least part of the container and at least part of the adaptor. The heat-shrinkable film maintains the adaptor blocked in rotation and in translation relative to the container when the heat-shrinkable film is in heat-shrunk condition.
The invention relates to upstream and/or downstream processes of selectively reducing one or more unpaired cysteines of a monoclonal antibody, whilst keeping conserved inter- and intra-molecular disulfide bonds elsewhere in the antibody intact. The invention further relates to purified antibodies obtained by the methods as described herein.
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
B01D 15/36 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction ionique, p. ex. échange d'ions, paire d'ions, suppression d'ions ou exclusion d'ions
B01D 15/20 - Adsorption sélective, p. ex. chromatographie caractérisée par des caractéristiques de structure ou de fonctionnement relatives au conditionnement de la matière adsorbante ou absorbante
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
31.
VALVE UNIT FOR A SYSTEM FOR PRODUCING A MEDICAL PREPARATION
A valve unit for a system for producing a medical preparation for parenteral nutrition is described. The valve unit includes a housing having a duct extending along a longitudinal access of housing, upper inlets and lower inlets, and an outlet in fluid communication with each of the inlets via the duct. The valve unit includes valves that alternately connect a respective upper inlet of the upper inlets and a respective lower inlet of the lower inlets to the duct. Each of the valves have a first passage that fluidly connects the respective upper inlet and the duct, and a second passage that fluidly connects the respective lower inlet and the duct.
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
A61J 1/20 - Dispositions pour le transfert des liquides, p. ex. du flacon à la seringue
An extravasation detection device, comprising: a cuff (3) comprising an elastic material adapted to be worn around a limb of a patient, wherein the cuff (3) is adapted to deform to accommodate for changes in the size of the limb, and at least one measuring means (5A-5D) connected to a section of the elastic material and adapted to deform with the section of the elastic material to detect an expansion of the section of the elastic material. Also described is a method (1000) for detecting an extravasation.
A61B 5/107 - Mesure de dimensions corporelles, p. ex. la taille du corps entier ou de parties de celui-ci
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
33.
Wearable medicament delivery device with leakage and skin contact sensing and method of use thereof
Described herein are wearable devices and methods for medicament delivery. Example devices can include a housing having an underside adapted to be proximate to a skin surface, and a reservoir disposed in the housing, the reservoir configured to be filled with a medicament to be delivered to the patient. The devices can include a cannula disposed within the housing and coupled to the reservoir, in which the cannula configured to protrude from a port defined by the housing to be positioned in the skin surface. The devices can further include a capacitive sensor configured to detect whether the medicament has leaked from the delivery device, in which the capacitive sensor includes a conductor disposed in a portion of the underside of the housing.
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
A61K 31/4015 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant des groupes oxo liés directement à l'hétérocycle, p. ex. piracétam, éthosuximide
Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for treating immune and inflammatory diseases and disorders; pharmaceutical preparations for treating autoimmune diseases, illnesses and conditions
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for treating immune and inflammatory diseases and disorders; pharmaceutical preparations for treating autoimmune diseases, illnesses and conditions
The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an histidine buffering agent such as histidine (or histidine buffer system such as histidine/imidazolium-histidine), and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
38.
PULSE WELDING METHOD AND WELDING TOOL FOR PULSE WELDING FOR A MEDICAL PACK FORMED AS A BAG
The invention relates to a welding tool and a method for pulse welding films of plastic for medical packs formed as bags. The invention generally provides for the film material that has been plastified during welding, and is consequently free-flowing, to be specifically displaced by increasing the sealing surface area. The displaced film material can for instance compensate for dimensional and form tolerances. At the same time, however, the strength of the welded seam region, which adjoins the interior space of the bag, is not reduced.
A flow control device (1) for an infusion system (2) comprises a base (10) for supporting a first fluid line (20A) and a second fluid line (20B) and a closure device (11) comprising an actuator (111) and at least one closure element (110) movable with respect to the base (10) by means of the actuator (111) to selectively act on the first or second fluid line (20A, 20B), when the first and second fluid lines (20A, 20B) are supported by the base (10), for closing or opening the respective fluid line (20A, 20B) for a fluid flow.
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
Described herein is a system (100) for agitating contents of at least one medical container (101), preferably a vial. The system comprises a holding device (104) defining at least one receptacle (103) for receiving the medical container, a mount assembly (105) for supporting the holding device. The mount assembly comprises a drive mechanism configured provide agitation motion to the holding device. The system further comprises a control unit (106) configured to control the agitation of the holding device and a gripping ami assembly (200) disposed with the holding device. The gripping arm assembly includes a gripping arm (201) arranged to hold the medical container positioned in the receptacle.
A sterile connection device includes two carriages configured to receive two tubes to be joined. A motor moves one carriage through a first portion of a path from an initial position in which the tubes are heated toward an intermediate position. At the time of this movement, the heated portion of each tube is at a temperature less than its melting temperature, with the movement severing the tubes and optionally moving heating elements of the carriages from a retracted condition toward a deployed condition. Movement of the carriage is paused at the intermediate position and the severed ends of the tubes are heated to a molten condition by the heating elements. Movement of the carriage then continues through a second portion of the path to a final position in which the heating elements retract (as necessary) to expose the severed ends of the tubes, which are joined together.
A61M 39/18 - Procédés ou appareils pour réaliser les connexions sous conditions stériles
A61M 39/14 - Raccords ou accouplements pour tubes pour connecter des tubes ayant des extrémités obturées
B29C 65/14 - Assemblage d'éléments préformésAppareils à cet effet par chauffage, avec ou sans pressage par énergie ondulatoire ou rayonnement corpusculaire
B29C 65/78 - Moyens pour la manipulation des éléments à assembler, p. ex. pour la fabrication de récipients ou d'objets creux
B29C 65/00 - Assemblage d'éléments préformésAppareils à cet effet
42.
INFUSION SYSTEM FOR ADMINISTERING A FLUID TO A PATIENT
An infusion system (S) for administering a fluid (F) to a patient via a fluid path (P), comprises: a pump (1) for conveying the fluid (F) along the fluid path (P), a separation device (2A-2D) in fluid connection with the fluid path (P) to separate gas (G) from the fluid (F) and a pressure- activated valve (3A, 3B) in fluid connection with the fluid path (P) at or downstream the separation device (2A-2D). Therein, it is provided that the separation device (2A-2D) defines a passage (20A-20C) for the fluid (F) and has an opening (21) covered by a gas-permeable, hydrophobic membrane (22) allowing gas (G) to exit from the fluid (F) through the opening (21).
The invention relates to a closure cap for a container filled with a medical liquid. The closure cap has at least one connection with a sealing element which can be pierced by a spike or a needle to remove the medical fluid. A flap is arranged on an inner side of the closure cap and is connected to the main body by means of a hinge. The sealing element is fixed to the closure cap by the flap folded against the main body.
The invention relates to an infusion bag (10), designed to be filled with a medical liquid. The infusion bag comprises at least one port (200), which is designed as a lower part (200) of a connector that has a head piece (208) having a connection region for an upper part (300) of the connector (20a, 20b). A sealing element (30) can be clamped in between the upper part (300) and the lower part (200). The lower part (200) comprises a welded portion (201), via which the lower part (200) is connected to at least a first chamber (15a) of the infusion bag (10). Between the welded portion (201) and the upper part (300), the lower part (200) comprises a flexible region (202) that can be clamped. The flexible region (202) that can be clamped forms a body having shoulders (209) and transitions into the head piece (208) via a neck (203). Between the sealing element (30) and the flexible region that can be clamped, the lower part (200) also comprises a puncturable membrane (207).
The invention relates to a system for filling pouches with a medical liquid. The system according to the invention comprises at least tree, particularly four, filling nozzles arranged one next to the other and laterally mutually spaced from one another. The components of a medical liquid can be filled in a pouch via one port each by means of the filling nozzles, and a first filling nozzle is laterally movable with respect to at least one other filling nozzle.
B65B 3/00 - Emballage de matériaux plastiques, de semi-liquides, de liquides ou de liquides et solides mélangés, dans des réceptacles ou récipients individuels, p. ex. dans des sacs ou sachets, boîtes, cartons, bidons ou pots
A61J 1/14 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques DétailsAccessoires à cet effet
A61J 1/20 - Dispositions pour le transfert des liquides, p. ex. du flacon à la seringue
B65B 3/04 - Procédés ou moyens pour charger le matériau dans les réceptacles ou récipients
A drug delivery assembly is provided for delivering a medicament to a patient via a fluid flow path. The assembly includes a main body having a body housing with a body interface and a controller. The assembly also includes a cartridge having a cartridge housing with a cartridge interface configured to be removably associated to the body interface. A drug reservoir positioned within the cartridge housing is configured to contain a medicament and includes an outlet. An adhesive pad is associated with a surface of the cartridge housing and is configured to removably attach to a human body surface. The controller is configured to execute a drug delivery routine in which at least a portion of the medicament in the drug reservoir is delivered to a subject via the outlet and the fluid flow path when the main body is coupled to the cartridge.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Protein for industrial use; Protein in raw material form for scientific and medical research; Proteins for use in manufacture; Proteins for use in the manufacture of food supplements
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for treating immune and inflammatory diseases and disorders; pharmaceutical preparations for treating autoimmune diseases, illnesses and conditions
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for treating immune and inflammatory diseases and disorders; pharmaceutical preparations for treating autoimmune diseases, illnesses and conditions
53.
COMPOSITIONS FOR PROVIDING PARENTERAL NUTRITION TO PEDIATRIC PATIENTS
A swing device for moving a blood bag includes a stand, a tray for receiving the blood bag, the tray being pivotable with respect to the stand, an electromotive drive device operatively coupled to the tray for causing a rocking movement of the tray with respect to the stand, and a control device for controlling operation of the drive device. The drive device includes a rotatable shaft member which is rotatable for driving the rocking movement of the tray. The drive device also includes a position encoding device configured to encode a rotary position of the rotatable shaft member of the drive device, wherein the control device is configured to determine a position of the tray with respect to the stand based on an encoder value indicative of the rotary position of the rotatable shaft member.
A drug delivery assembly includes a main body and a cartridge. The body includes a housing, an adhesive pad, and a body interface that detachably associates with a cartridge interface of the cartridge. A fluid flow path extends through the body housing, between a first end configured to open a seal of the cartridge and a second end configured to enter a human body. The cartridge contains a drug reservoir having an outlet and holding a medicament. The seal prevents the medicament from exiting the reservoir and maintains pressure within the reservoir until the seal is opened by the first end of the fluid flow path when the cartridge is coupled to the main body, placing the reservoir into fluid communication with the flow path. A controller actuates a valve within the body to selectively allow and prevent flow through the flow path during an automated drug delivery routine.
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
A61M 5/20 - Seringues automatiques, p. ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
An on-body drug delivery device having a housing carried by a substrate. The device includes an adhesive module placed over at least a portion of said device to provide added securement of the device to the patient's body.
The invention relates to a piston stopper (10) for a medical syringe (1) wherein the piston stopper (10) has an end wall (11), a lateral wall (12) and an internal thread (16) for securing a piston rod (7). The piston stopper (10) comprises a main body (10a) which made of a cycloolefin, in particular a cycloloefin copolymer or a cycloolefin polymer. A plurality of sealing rings (13a-13d) that are made from a plastic material extend around the main body of the piston (10) and are materially bonded to the main body of the piston (10a). The invention furthermore relates to a medical syringe (1) and to a method for the production thereof.
An on-body drug delivery device having a housing and a cartridge removably attachable to the housing. The cartridge comprises: a drug chamber, a piston received in the drug chamber movable from a first, initial position to a second position, an actuation device for moving the piston from the first position to the second position, and at least one breakable sterility sensor circuit formed by attachment of the cartridge to the housing, the circuit being closed when the cartridge is properly attached to the housing and broken if the cartridge is not properly attached to the housing or removed from the housing after being attached thereto, and/or the circuit being broken if the piston is not in the initial position when the cartridge is first attached to the housing.
A61M 5/50 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras avec des moyens pour empêcher la réutilisation ou pour indiquer si le dispositif est défectueux, usagé, non stérile ou si l'on a tenté de l'utiliser
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
A balloon catheter (1) for enteral feeding comprises a tube (10) for extending through a stoma (S) of a patient (P); an outer member (11) fixed on the tube (10) to rest against the patient's (P) skin (A); and an inflatable balloon (12) to rest against an internal patient's (P) lumen wall (G) in an inflated condition, wherein a pressure sensor (130) arranged to obtain sensor values of a pressure in a fluid system (F) comprising an inner volume (120) of the balloon (12), and an antenna (131) for wirelessly communicating sensor data based on the sensor values are provided.
A catheter (1) for percutaneous feeding comprises a tube (10) for extending through a stoma (S) of a patient (P); an outer member (11) fixed or fixable on the tube (10) to rest against the patient's (P) skin (A); and an inner member (12) fixed or fixable on the tube (10) to rest against an internal patient's (P) lumen wall (G). It is provided that the tube (10) comprises a stretchable section (100A-100D) arrangeable between the outer member (11) and the inner member (12) being stretchable in length, wherein a retaining structure (13A-13D) is provided limiting the length of the stretchable section (100A-100D).
A prefilled syringe and a method of filling a syringe with a pegfilgrastim solution to provide a target extracted volume of pegfilgrastim solution from the syringe are described. A method includes selecting the target extracted volume of pegfilgrastim solution, determining an estimated drug transfer loss, determining an estimated syringe dead volume, filling the syringe with a volume of pegfilgrastim solution comprising at least the target extracted volume plus the estimated drug transfer loss plus the estimated syringe dead volume.
The invention relates to a piston stopper for a medical syringe. The piston stopper has an end wall, a side wall and an internal thread for securing a plunger rod, wherein the piston stopper is made of a butyl rubber. The end wall is conical in the distal direction both on the outside and on the inside. The end wall merges towards the side wall into a first sealing ring which extends around the circumference of the side wall. The side wall has at least three further sealing rings. Further, the invention relates to a medical syringe provided with the plunger stopper.
The invention relates to a syringe body having a nozzle and a threaded connection. The syringe body consists of an inner part and an outer part, the inner part comprising, at least in regions, a cycloolefin, in particular a cycloolefin copolymer or a cycloolefin polymer, as a first material. The first material forms an inner wall of the syringe body. The threaded connection of the outer part comprises, at least in regions, a material different from the cycloolefin as a second material. The invention further relates to a syringe having the syringe body.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for human use for treating immune and inflammatory diseases and disorders; pharmaceutical preparations for human use for treating autoimmune diseases, illnesses and conditions, none of the aforesaid goods being antifungal drugs, antifungal preparations or preparations for treating fungal diseases
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for human use for treating immune and inflammatory diseases and disorders; pharmaceutical preparations for human use for treating autoimmune diseases, illnesses and conditions
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for human use for the treatment of oncological and metabolic diseases and disorders; pharmaceutical preparations for human use for the prevention of fractures; pharmaceutical preparations for human use for prevention of pain associated with oncological and metabolic diseases and disorders; pharmaceutical preparations for human use for surgery, namely, for prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors; pharmaceutical preparations for human use for radiotherapy, namely, for prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors; pharmaceutical preparations for human use for the treatment and prevention of bone metastases, solid tumors, osteolytic bone lesions of multiple myeloma, hypercalcemia of malignancy, giant cell tumor of bone
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for human use for the treatment of oncological and metabolic diseases and disorders; pharmaceutical preparations for human use for the prevention of fractures; pharmaceutical preparations for human use for prevention of pain associated with oncological and metabolic diseases and disorders; pharmaceutical preparations for human use for surgery, namely, for prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors; pharmaceutical preparations for human use for radiotherapy, namely, for prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors; pharmaceutical preparations for human use for the treatment and prevention of bone metastases, solid tumors, osteolytic bone lesions of multiple myeloma, hypercalcemia of malignancy, giant cell tumor of bone
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for human use for the treatment of oncological and metabolic diseases and disorders; pharmaceutical preparations for human use for the prevention of fractures; pharmaceutical preparations for human use for prevention of pain associated with oncological and metabolic diseases and disorders; pharmaceutical preparations for human use for surgery, namely, for prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors; pharmaceutical preparations for human use for radiotherapy, namely, for prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors; pharmaceutical preparations for human use for the treatment and prevention of bone metastases, solid tumors, osteolytic bone lesions of multiple myeloma, hypercalcemia of malignancy, giant cell tumor of bone
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for human use for the treatment of bone diseases and disorders; pharmaceutical preparations for human use for the treatment and prevention of osteoporosis
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for human use for the treatment of bone diseases and disorders; pharmaceutical preparations for human use for the treatment and prevention of osteoporosis
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for human use for the treatment of bone diseases and disorders; pharmaceutical preparations for human use for the treatment and prevention of osteoporosis
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for human use for the treatment of bone diseases and disorders; pharmaceutical preparations for human use for the treatment and prevention of osteoporosis
The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an histidine buffering agent such as histidine (or histidine buffer system such as histidine/imidazolium-histidine), and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
A clamping device for acting onto a medical tubing includes a clamp arrangeable on the medical tubing and displaceable between an open position in which the clamp unblocks the medical tubing and a close position in which the clamp closes the medical tubing. The clamping device further includes a drive system configured to act on the clamp for switching the clamp between the open position and the close position. The clamping device also includes a main control circuit and a secondary control circuit electronically independent from the main control circuit, and a relay switchable between a first position and a second position. In the first position, the relay electronically couples the drive system to the main control circuit while the drive system is electronically decoupled from the secondary control circuit. In the second position, the relay electronically couples the drive system to the secondary control circuit while the drive system is electronically decoupled from the main control circuit. The secondary control circuit causes the clamp to adopt the close position when the relay is in the second position.
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for human use; Medical preparations; none of the aforesaid goods being antifungal drugs, antifungal preparations or preparations for treating fungal diseases.
The present invention is directed to use of kifunensine for increasing sialylation of a glycosylated polypeptide, wherein a cell that produces the glycosylated polypeptide is contacted with kifunensine. Also provided are related methods for increasing sialylation of a glycosylated polypeptide and producing a glycosylated polypeptide, as well as glycosylated polypeptides and pharmaceutical compositions comprising the same, and their use in medicine.
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C12P 21/00 - Préparation de peptides ou de protéines
92.
SYRINGE, SYRINGE BODY AND METHOD FOR THE PRODUCTION THEREOF
The disclosure relates to a syringe, comprising a syringe body with a nozzle and a threaded connection. The syringe body comprises a side wall and a front wall, wherein the syringe body comprises a cycloolefin as a first material, at least in portions. The first material forms an internal wall of the syringe body. The threaded connection comprises, at least in portions, as a second material a material other than the cycloolefin, wherein the first and the second material are integrally bonded to one another. The second material extends in the region of the front wall at least in portions over the first material, so that the front wall comprises, at least in portions, a two-layer region. The first and the second material in the two-layer region have a mutually engaging structure.
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
A welding apparatus (1) for radio-frequency, RF, welding, comprises: a clamp (10) having two electrodes (100, 101; 100′, 101′) being movable with respect to one another for clamping one or more items (2; 2′) therebetween for a welding process; and an RF power supply (11) for providing an RF welding current to the electrodes (100, 101; 100′, 101′) of the clamp (10), the RF power supply being adapted to change the frequency of the RF welding current during the welding process.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections
95.
Connector and Connection System for a Medical Packaging, and Method for Providing a Liquid for a Medical Packaging
The invention relates to a connector for a medical packaging. The connector comprises an attachment part with a sealing element, the sealing element having a sealing head with at least one slit. The sealing head sits in an inner sleeve of the attachment part, the sealing head being adjoined by at least one trunk portion, which has a larger outer diameter than the sealing head. A gap is present between the at least one trunk portion and an opposite inner wall of the attachment part. An interior of the sealing element is free from a body with a tip that is intended to assist the opening of the sealing head. The attachment part has an outer sleeve which surrounds the inner sleeve and which has an internal thread.
The invention relates to a process for manufacturing oil-in-water emulsions with a PFAT5 value that remains below 0.05 % for at least 24 hours, preferably for at least 48 hours after admixing the emulsions with an amino acid and a glucose solution suitable for parenteral administration.
A23D 7/005 - Compositions à base d'huiles ou de graisses comestibles contenant une phase aqueuse, p. ex. margarines caractérisées par des ingrédients autres que des triglycérides d'acides gras
A23D 7/01 - Autres esters d'acides gras, p. ex. phosphatides
An on-body drug delivery device having a housing carried by a substrate. The device includes an adhesive module placed over at least a portion of said device to provide added securement of the device to the patient's body.
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61L 24/06 - Adhésifs ou ciments chirurgicauxAdhésifs pour dispositifs de colostomie contenant des matériaux macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons carbone-carbone non saturées
